Category: Zacks Small Cap Research

1333435363746350 / 456 POSTS
By David Bautz, PhDTSX:ATE.VOn March 20, 2018, Antibe Therapeutics Inc. (TSX:ATE.V) announced positive topline results for the Phase 2 gastrointestinal (GI) safety study of its lead drug, ATB-346. The double-blind, gastrointestinal (GI) safety study ...
By Steven Ralston, CFANASDAQ:DSKE SUMMARY OF RECENT EVENTS• On March 16, 2018, Daseke (NASDAQ:DSKE) announced financial results for the full year of 2017 • Total revenues increased 29.8% to $846.3 million, primarily due to the seven ...
OTC:AXIMSummary• AXIM Biotechnologies (OTC:AXIM) holds the intellectual property rights to the controlled-release, trans-mucosal (chewing gum) drug delivery platform for medical cannabinoids. o The company is pursuing several indications: • Irritable ...
By David Bautz, PhDNASDAQ:TNXPBusiness UpdateHONOR Study Nearing 50% EnrollmentIn 2017, Tonix (NASDAQ:TNXP) announced the first patient was enrolled in the Phase 3 HONOR study of TNX-102 SL 5.6 mg for the treatment of posttraumatic stress disorder (P ...
By John Vandermosten, CFANASDAQ:CRMEFor its fourth quarter and full year, Cardiome Pharma Corp (NASDAQ:CRME) reported revenues of $7.0 million and $24.0 million respectively, a (0.3%) and (5.1%) decline.  Fourth quarter net loss was ($8.3) million or ...
By Brian Marckx, CFANASDAQ:CTSOCytoSorbents (NASDAQ:CTSO) reported financial results for their fourth quarter ending December 31st and provided a business update.  Product sales continue their regular and rapid climb upward, setting another record an ...
By David Bautz, PhDNASDAQ:ARLZBusiness UpdateContinued Growth in Zontivity®Aralez (NASDAQ:ARLZ) launched Zontivity® in June 2017 and is now promoting the drug with the company’s 75 person sales force to approximately 12,000 cardiologists, primary car ...
By David Bautz, PhDNASDAQ:OPNTBusiness UpdateOpioid Crisis Continues to WorsenA new report from the Centers for Disease Control (CDC) shows that emergency department visits for opioid overdoses rose 30% in the U.S. from July 2016 to September 2017. T ...
By David Bautz, PhDNASDAQ:VKTXBusiness UpdateViking Therapeutics, Inc. (NASDAQ:VKTX) is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. The company’s lead compounds include: VK5211, which is being developed fo ...
OTC: HSSHFIntroduced in 2009, Bitcoin was the first decentralized digital currency. One Bitcoin was worth roughly $0.003 in early 2010, according to Coinmarketcap.com data. By September of 2017, the Bitcoin / dollar exchange rate had climbed to over ...
1333435363746350 / 456 POSTS